These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8055682)

  • 61. Dosing in neonates: special considerations in physiology and trial design.
    Ku LC; Smith PB
    Pediatr Res; 2015 Jan; 77(1-1):2-9. PubMed ID: 25268145
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reported use of antimicrobial agents in children attending a pediatric emergency department.
    Barnett ED; Pelton SI; Vinci RJ; Stottmeier KD
    Pediatr Infect Dis J; 1991 Dec; 10(12):949-50. PubMed ID: 1766713
    [No Abstract]   [Full Text] [Related]  

  • 63. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.
    Müller M; dela Peña A; Derendorf H
    Antimicrob Agents Chemother; 2004 May; 48(5):1441-53. PubMed ID: 15105091
    [No Abstract]   [Full Text] [Related]  

  • 64. Bioavailability determination of two crystal forms of sulfameter in humans from urinary excretion data.
    Khalafallah N; Khalil SA; Moustafa MA
    J Pharm Sci; 1974 Jun; 63(6):861-4. PubMed ID: 4850765
    [No Abstract]   [Full Text] [Related]  

  • 65. ["Prescription and monitoring of anti-infectives in adults and children"].
    Picard L; Patrat-Delon S; Revest M; Tattevin P
    Rev Prat; 2021 Mar; 71(3):e83-e91. PubMed ID: 34161048
    [No Abstract]   [Full Text] [Related]  

  • 66.
    Schmidt JJ; Eden G; Seffer MT; Winkler M; Kielstein JT
    Clin Kidney J; 2020 Jun; 13(3):421-424. PubMed ID: 32699622
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Prescription and monitoring of the most common classes of drugs in adults and children, excluding anti-infectives. Know the proper use of the main therapeutic classes. Part 8a. Contraceptives].
    Duranteau L; Dubost E
    Rev Prat; 2022 Mar; 72(3):335-339. PubMed ID: 35638968
    [No Abstract]   [Full Text] [Related]  

  • 68. Regulatory approval for anti-infectives in children.
    Hiruy H; Smith T; Yao L; Farley J; Nambiar S
    Lancet Child Adolesc Health; 2021 Jun; 5(6):e26. PubMed ID: 34019792
    [No Abstract]   [Full Text] [Related]  

  • 69. Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics.
    Tan Y; Cui A; Qian L; Li C; Wu Z; Yang Y; Han P; Huang X; Diao L
    Front Pharmacol; 2023; 14():1101991. PubMed ID: 36755948
    [No Abstract]   [Full Text] [Related]  

  • 70. Advances in Drug Discovery and Development for Pediatric Tuberculosis.
    Hoagland D; Zhao Y; Lee RE
    Mini Rev Med Chem; 2016; 16(6):481-97. PubMed ID: 26202201
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.
    Fernandez E; Perez R; Hernandez A; Tejada P; Arteta M; Ramos JT
    Pharmaceutics; 2011 Feb; 3(1):53-72. PubMed ID: 24310425
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gentamicin dosing for pediatric patients with congenital heart disease.
    Moffett BS; Bork SJ; Mott AR
    Pediatr Cardiol; 2010 Aug; 31(6):761-5. PubMed ID: 20549198
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.
    Leslie LK; Newman TB; Chesney PJ; Perrin JM
    Pediatrics; 2005 Jul; 116(1):195-204. PubMed ID: 15995053
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of teicoplanin in an ICU population of children and infants.
    Lukas JC; Karikas G; Gazouli M; Kalabalikis P; Hatzis T; Macheras P
    Pharm Res; 2004 Nov; 21(11):2064-71. PubMed ID: 15587929
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.
    Corvaisier S; Charpiat B; Mounier C; Wallon M; Leboucher G; Al Kurdi M; Chaulet JF; Peyron F
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3794-800. PubMed ID: 15388436
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.
    Singh J; Burr B; Stringham D; Arrieta A
    Paediatr Drugs; 2001; 3(10):733-61. PubMed ID: 11706924
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
    Burger DM; van Rossum AM; Hugen PW; Suur MH; Hartwig NG; Geelen SP; Scherpbier HJ; Hoetelmans RM; Vulto AG; de Groot R;
    Antimicrob Agents Chemother; 2001 Mar; 45(3):701-5. PubMed ID: 11181346
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.
    Sokal EM; Roberts EA; Mieli-Vergani G; McPhillips P; Johnson M; Barber J; Dallow N; Boxall E; Kelly D
    Antimicrob Agents Chemother; 2000 Mar; 44(3):590-7. PubMed ID: 10681323
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibiotics in neonatal infections: a review.
    Fanos V; Dall'Agnola A
    Drugs; 1999 Sep; 58(3):405-27. PubMed ID: 10493270
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.
    Principi N; Esposito S
    Drug Saf; 1999 Jan; 20(1):25-41. PubMed ID: 9935275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.